| Targeting cell cycle in breast cancer: CDK4/6 inhibitors M Piezzo, S Cocco, R Caputo, D Cianniello, GD Gioia, VD Lauro, G Fusco, ... International journal of molecular sciences 21 (18), 6479, 2020 | 115 | 2020 |
| Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives S Cocco, M Piezzo, A Calabrese, D Cianniello, R Caputo, V Di Lauro, ... International journal of molecular sciences 21 (13), 4579, 2020 | 97 | 2020 |
| Programmed death ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patients G Botti, F Collina, G Scognamiglio, F Rao, V Peluso, R De Cecio, ... International journal of molecular sciences 18 (2), 459, 2017 | 97 | 2017 |
| Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis M Piezzo, P Chiodini, M Riemma, S Cocco, R Caputo, D Cianniello, ... International journal of molecular sciences 21 (17), 6400, 2020 | 81 | 2020 |
| Multiple effects of ascorbic acid against chronic diseases: Updated evidence from preclinical and clinical studies M Berretta, V Quagliariello, N Maurea, R Di Francia, S Sharifi, G Facchini, ... Antioxidants 9 (12), 1182, 2020 | 78 | 2020 |
| Targeting autophagy in breast cancer S Cocco, A Leone, M Piezzo, R Caputo, V Di Lauro, F Di Rella, G Fusco, ... International journal of molecular sciences 21 (21), 7836, 2020 | 74 | 2020 |
| Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative … S Cocco, A Leone, MS Roca, R Lombardi, M Piezzo, R Caputo, ... Journal of Translational Medicine 20 (1), 290, 2022 | 35 | 2022 |
| Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights … ME Cazzaniga, M Airoldi, V Arcangeli, S Artale, F Atzori, A Ballerio, ... The Breast 35, 115-121, 2017 | 25 | 2017 |
| The use of tocilizumab in patients with COVID-19: a systematic review, meta-analysis and trial sequential analysis of randomized controlled studies AE Maraolo, A Crispo, M Piezzo, P Di Gennaro, MG Vitale, D Mallardo, ... Journal of clinical medicine 10 (21), 4935, 2021 | 23 | 2021 |
| Gene expression assay in the management of early breast cancer R Caputo, D Cianniello, A Giordano, M Piezzo, M Riemma, M Trovò, ... Current Medicinal Chemistry 27 (17), 2826-2839, 2020 | 23 | 2020 |
| A psychosocial genomics pilot study in oncology for verifying clinical, inflammatory and psychological effects of mind-body transformations-therapy (MBT-T) in breast cancer … M Cozzolino, S Cocco, M Piezzo, G Celia, S Costantini, V Abate, ... Journal of Clinical Medicine 10 (1), 136, 2021 | 19 | 2021 |
| Clinical trials and drug cost savings for Italian health service F D’Ambrosio, G De Feo, G Botti, A Capasso, S Pignata, P Maiolino, ... BMC health services research 20, 1-7, 2020 | 14 | 2020 |
| Uptake of trastuzumab biosimilars for the treatment of HER2-positive breast cancer: a real-world experience from a cancer center M Piezzo, R D’Aniello, I Avallone, B Barba, D Cianniello, S Cocco, ... Pharmaceutics 13 (5), 684, 2021 | 10 | 2021 |
| Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis R Caputo, G Buono, M Piezzo, C Martinelli, D Cianniello, A Rizzo, ... Frontiers in Oncology 14, 1362641, 2024 | 4 | 2024 |
| Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged≥ 65 years: new lessons for clinical practice from the EVA study M Cazzaniga, C Verusio, M Ciccarese, A Fumagalli, D Sartori, C Ancona, ... Oncotarget 9 (61), 31877, 2018 | 3 | 2018 |
| Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR plus) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New … ME Cazzaniga, M Airoldi, V Arcangeli, S Artale, F Atzori, A Ballerio, ... Breast 35, 115-121, 2017 | 3 | 2017 |
| 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer E Blondeaux, L Boni, T Ruelle, V Di Lauro, C Molinelli, M Piezzo, B Fratini, ... Annals of Oncology 32, S497-S498, 2021 | 2 | 2021 |
| Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study. G Mustacchi, P Pronzato, G Arpino, A D'Alonzo, M Piezzo, C Natoli, ... Journal of Clinical Oncology 37 (15_suppl), e12549-e12549, 2019 | 2 | 2019 |
| Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC … ME Cazzaniga, P Pronzato, I Meattini, L Biganzoli, C Taverniti, C Natoli, ... Journal of Clinical Oncology 36 (15_suppl), e13081-e13081, 2018 | 2 | 2018 |
| 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a … L Cerbone, E Blondeaux, L Boni, T Ruelle, S Russo, M Bonotto, G Targato, ... Annals of Oncology 32, S475-S476, 2021 | | 2021 |
